Modulation of diabetes in NOD mice by GAD65-specific monoclonal antibodies is epitope specific and accompanied by anti-idiotypic antibodies

Immunology

Volumn 123, Issue 4, 2008, Pages 547-554

  Hall, Tyler R ^a   Bogdani, Marika ^b   LeBoeuf, Renee C ^a   Kirk, Elizabeth A ^a   Maziarz, Marlena ^a   Banga, J Paul ^c   Oak, Shilpa ^a   Pennington, Christina A ^a   Hampe, Christiane S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Pacific North west Research Institute   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Anti idiotypic antibodies; Autoantibodies; Autoimmune diabetes; GAD65; NOD mouse

Indexed keywords

EPITOPE; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNE DISEASE; BODY WEIGHT; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG INHIBITION; FEMALE; HUMAN; IMMUNOMODULATION; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; BINDING, COMPETITIVE; DIABETES MELLITUS, TYPE 1; EPITOPES; FEMALE; GLUTAMATE DECARBOXYLASE; IMMUNOGLOBULIN G; ISLETS OF LANGERHANS; MICE; MICE, INBRED NOD; MOLECULAR SEQUENCE DATA; SEQUENCE ALIGNMENT; SEVERITY OF ILLNESS INDEX; WEIGHT LOSS;

EID: 39549091299     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2007.02724.x     Document Type: Article

References (55)

1. Shoda LK, Young DL, Ramanujan S et al. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 2005 23 : 115 26.
2. Bach J-F. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocrine Rev 1994 15 : 516 42.
3. Singh B, Rabinovitch A. Influence of microbial agents on the development and prevention of autoimmune diabetes. Autoimmunity 1993 15 : 209 13.
4. Ohsugi T, Kurosawa T. Increased incidence of diabetes mellitus in specific pathogen-eliminated offspring produced by embryo transfer in NOD mice with low incidence of the disease. Lab Anim Sci 1994 44 : 386 8.
5. Haskins K. Pathogenic T-cell clones in autoimmune diabetes: more lessons from the NOD mouse. Adv Immunol 2005 87 : 123 62.
6. Wong FS, Wen L. B cells in autoimmune diabetes. Rev Diabet Stud 2005 2 : 121 35.
7. Serreze DV, Chapman HD, Varnum DS et al. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new 'speed congenic' stock of NOD Ig mu null mice. J Exp Med 1996 184 : 2049 53.
8. Atkinson MA, Leiter EH. The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med 1999 5 : 601 4.
9. Bach JF. Immunotherapy of type 1 diabetes: lessons for other autoimmune diseases. Arthritis Res 2002 4 : S3 15.
10. Maki T, Ichikawa T, Blanco R, Porter J. Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum. Proc Natl Acad Sci USA 1992 89 : 3434 8.
11. Makhlouf L, Grey ST, Dong V et al. Depleting anti-CD4 monoclonal antibody cures new-onset diabetes, prevents recurrent autoimmune diabetes, and delays allograft rejection in nonobese diabetic mice. Transplantation 2004 77 : 990 7.
12. Herold KC, Hagopian W, Auger JA et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002 346 : 1692 8.
13. Kaufman DL, Clare-Salzler M, Tian J et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993 366 : 69 72.
14. Ramiya VK, Lan MS, Wasserfall CH, Notkins AL, Maclaren NK. Immunization therapies in the prevention of diabetes. J Autoimmun 1997 10 : 287 92.
15. Jun H-S, Chung Y-H, Han J, Kim A, Yoo SS, Sherwin RS, Yoon J-W. Prevention of autoimmune diabetes by immunogene therapy using recombinant vaccinia virus expressing glutamic acid decarboxylase. Diabetologia 2002 45 : 668 76.
16. Petersen JS, Karlsen AE, Markholst H, Worsaae A, Dyrberg T, Michelsen B. Neonatal tolerization with glutamic acid decarboxylase but not with bovine serum albumin delays the onset of diabetes in NOD mice. Diabetes 1994 43 : 1478 84.
17. Tisch R, Yang XD, Liblau RS, McDevitt HO. Administering glutamic acid decarboxylase to NOD mice prevents diabetes. J Autoimmun 1994 7 : 845 50.
18. Kim J, Richter W, Aanstoot H-J et al. Differential expression of GAD65 and GAD67 in human, rat, and mouse pancreatic islets. Diabetes 1993 42 : 1799 808.
19. Tisch R, Liblau RS, Yang XD, Liblau P, McDevitt HO. Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes 1998 47 : 894 9.
20. Tisch R, Wang B, Serreze DV. Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent. J Immunol 1999 163 : 1178 87.
21. Weaver DJ Jr., Liu B, Tisch R. Plasmid DNAs encoding insulin and glutamic acid decarboxylase 65 have distinct effects on the progression of autoimmune diabetes in nonobese diabetic mice. J Immunol 2001 167 : 586 92.
22. Bot A, Smith D, Bot S et al. Plasmid vaccination with insulin B chain prevents autoimmune diabetes in nonobese diabetic mice. J Immunol 2001 167 : 2950 5.
23. Tisch R, Wang B, Weaver DJ, Liu B, Bui T, Arthos J, Serreze DV. Antigen-specific mediated suppression of beta cell autoimmunity by plasmid DNA vaccination. J Immunol 2001 166 : 2122 32.
24. Cetkovic-Cvrlje M, Gerling IC, Muir A, Atkinson MA, Elliot JF, Leiter EH. Retardation or acceleration of diabetes in NOD/Lt mice mediated by intrathymic administration of candidate beta-cell antigens. Diabetes 1997 46 : 1975 82.
25. Ziegler B, Augstein P, Luhder F et al. Monoclonal antibodies specific to the glutamic acid decarboxylase 65 kDa isoform derived from a non-obese diabetic (NOD) mouse. Diabetes Res 1994 25 : 47 64.
26. Velloso LA, Eizirik DL, Karlsson FA, Kampe O. Absence of autoantibodies against glutamate decarboxylase (GAD) in the non-obese diabetic (NOD) mouse and low expression of the enzyme in mouse islets. Clin Exp Immunol 1994 96 : 129 37.
27. Bonifacio E, Atkinson M, Eisenbarth G, Serreze D, Kay TW, Lee-Chan E, Singh B. International Workshop on Lessons From Animal Models for Human Type 1 Diabetes: identification of insulin but not glutamic acid decarboxylase or IA-2 as specific autoantigens of humoral autoimmunity in nonobese diabetic mice. Diabetes 2001 50 : 2451 8.
28. Jaume JC, Parry SL, Madec AM, Sonderstrup G, Baekkeskov S. Suppressive effect of glutamic acid decarboxylase 65-specific autoimmune B lymphocytes on processing of T cell determinants located within the antibody epitope. J Immunol 2002 169 : 665 72.
29. Banga JP, Moore JK, Duhindan N, Madec AM, Van Endert PM, Orgiazzi J, Endl J. Modulation of antigen presentation by autoreactive B cell clones specific for GAD65 from a type I diabetic patient. Clin Exp Immunol 2004 135 : 74 84.
30. Reijonen H, Daniels TL, Lernmark A, Nepom GT. GAD65-specific autoantibodies enhance the presentation of an immunodominant T-cell epitope from GAD65. Diabetes 2000 49 : 1621 6.
31. Menard V, Jacobs H, Jun HS, Yoon JW, Kim SW. Anti-GAD monoclonal antibody delays the onset of diabetes mellitus in NOD mice. Pharm Res 1999 16 : 1059 66.
32. Padoa CJ, Banga JP, Madec AM et al. Recombinant Fabs of human monoclonal antibodies specific to the middle epitope of GAD65 inhibit type 1 diabetes-specific GAD65Abs. Diabetes 2003 52 : 2689 95.
33. Gilliam LK, Binder KA, Banga JP et al. Multiplicity of the antibody response to GAD65 in Type I diabetes. Clin Exp Immunol 2004 138 : 337 41.
34. Schlosser M, Banga JP, Madec AM et al. Dynamic changes of GAD65 autoantibody epitope specificities in individuals at risk of developing type 1 diabetes. Diabetologia 2005 48 : 922 30.
35. Raju R, Foote J, Banga JP et al. Analysis of GAD65 autoantibodies in stiff-person syndrome patients. J Immunol 2005 175 : 7755 62.
36. Tremble J, Morgenthaler NG, Vlug A, Powers AC, Christie MR, Scherbaum WA, Banga JP. Human B cells secreting immunoglobulin G to glutamic acid decarboxylase-65 from a nondiabetic patient with multiple autoantibodies and Graves' disease: a comparison with those present in type 1 diabetes. J Clin Endocrinol Metab 1997 82 : 2664 70.
37. Schwartz HL, Chandonia JM, Kash SF et al. High-resolution autoreactive epitope mapping and structural modeling of the 65 kDa form of human glutamic acid decarboxylase. J Mol Biol 1999 287 : 983 99.
38. Fenalti G, Hampe CS, O'Connor K, Banga JP, Mackay IR, Rowley MJ, El-Kabbani O. Molecular characterization of a disease associated conformational epitope on GAD65 recognised by a human monoclonal antibody b96.11. Mol Immunol 2007 44 : 1178 89.
39. Grubin CE, Daniels T, Toivola B et al. A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia 1994 37 : 344 50.
40. Falorni A, Örtqvist E, Persson B, Lernmark Å. Radioimmunoassays for glutamic acid decarboxylase (GAD65) and GAD65 autoantibodies using 35S or 3H recombinant human ligands. J Immunol Meth 1995 186 : 89 99.
41. Peterson JW, Comer JE, Noffsinger DM et al. Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax. Infect Immun 2006 74 : 1016 24.
42. Jerne NK. Towards a network theory of the immune system. Ann Immunol (Paris) 1974 125C : 373 89.
43. Stea EA, Routsias JG, Clancy RM, Buyon JP, Moutsopoulos HM, Tzioufas AG. Anti-La/SSB antiidiotypic antibodies in maternal serum: a marker of low risk for neonatal lupus in an offspring. Arthritis Rheum 2006 54 : 2228 34.
44. Rossi F, Dietrich G, Kazatchkine MD. Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses. Immunol Rev 1989 110 : 135 49.
45. Silvestris F, Bankhurst AD, Searles RP, Williams RC Jr. Studies of anti-F (ab′) 2 antibodies and possible immunologic control mechanisms in systemic lupus erythematosus. Arthritis Rheum 1984 27 : 1387 96.
46. Jayne DR, Esnault VL, Lockwood CM. Anti-idiotype antibodies to anti-myeloperoxidase autoantibodies in patients with systemic vasculitis. J Autoimmun 1993 6 : 221 6.
47. Rossi F, Jayne DR, Lockwood CM, Kazatchkine MD. Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol 1991 83 : 298 303.
48. Escher R, Muller D, Vogel M, Miescher S, Stadler BM, Berchtold P. Recombinant human natural autoantibodies against GPIIb/IIIa inhibit binding of autoantibodies from patients with AITP. Br J Haematol 1998 102 : 820 8.
49. Escher R, Vogel M, Escher G, Miescher S, Stadler BM, Berchtold P. Recombinant anti-idiotypic antibodies inhibit human natural anti-glycoprotein (GP) IIb/IIIa autoantibodies. J Autoimmun 2002 18 : 71 81.
50. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001 345 : 747 55.
51. Sapir T, Shoenfeld Y. Facing the enigma of immunomodulatory effects of intravenous immunoglobulin. Clin Rev Allergy Immunol 2005 29 : 185 99.
52. Panto F, Giordano C, Amato MP, Pugliese A, Donatelli M, D'Acquisto G, Galluzzo A. The influence of high dose intravenous immunoglobulins on immunological and metabolic pattern in newly diagnosed type I diabetic patients. J Autoimmun 1990 3 : 587 92.
53. Colagiuri S, Leong GM, Thayer Z, Antony G, Dwyer JM, Kidson W, Wakefield D. Intravenous immunoglobulin therapy for autoimmune diabetes mellitus. Clin Exp Rheumatol 1996 14 : S93 7.
54. Dalakas MC. The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies. J Neurol 2005 252 : I19 25.
55. Elias D, Bone AJ, Baird JD, Cooke A, Cohen IR. Insulin-mimicking anti-idiotypic antibodies in development of spontaneous autoimmune diabetes in BB/E rats. Diabetes 1990 39 : 1467 71.